CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item5.02

Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On January17, 2017, Mark Lampert resigned from the Board of
Directors of Cascadian Therapeutics, Inc.Mr.Lamperts resignation
was the result of his disagreement with decisions made by the
Board of Directors related to the recently announced public
offering. A copy of Mr.Lamperts resignation letter is attached as
Exhibit 17.1 to this report on Form 8-K.

Item9.01 Financial Statements and Exhibits

(d)
Exhibits.

Exhibit

Number

Description

17.1 Director Resignation Letter

2


About CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC)

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) Recent Trading Information

CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) closed its last trading session up +0.06 at 3.78 with 4,123,544 shares trading hands.

An ad to help with our costs